ACM
TSHA icon

Aster Capital Management’s Taysha Gene Therapies TSHA Stock Holding History

Aster Capital Management’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$126K Buy
+18,553
New +$110K 0.03% 475
2025
Q4 		– Sell
-1,280
Closed -$4.19K – 1426
2025
Q3 		$4.19K Buy
+1,280
New +$3.62K ﹤0.01% 820

Other funds holding TSHA

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Aster Capital Management's TSHA Position: Q2 2026 in Review

Aster Capital Management opened a new position in Taysha Gene Therapies (TSHA) in Q2 2026: 18,553 shares worth $126K. The stake represents 0.03% of the portfolio and ranks #475 among its holdings. This is a return to the name: Aster Capital Management previously reported a position in TSHA as recently as Q3 2025.

Aster Capital Management first reported a position in TSHA in Q3 2025 and has held it in 2 quarters since. 208 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • Aster Capital Management held 18,553 shares of Taysha Gene Therapies worth $126K as of Q2 2026.
  • Taysha Gene Therapies was a new Aster Capital Management position in Q2 2026.
  • Taysha Gene Therapies made up 0.03% of Aster Capital Management's portfolio in Q2 2026, its #475 holding.
  • Aster Capital Management first reported a position in Taysha Gene Therapies in Q3 2025 and has held it in 2 quarters since.
  • 208 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Aster Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.